09:12 AM EDT, 08/28/2024 (MT Newswires) -- Vaxart ( VXRT ) said Wednesday that preclinical data on its mucosal vaccine platform suggest a potential for treating HPV-related cervical dysplasia.

The company said its human papillomavirus, or HPV, vaccine constructs can stimulate an immune response against HPV16 proteins and reduce tumor size in mice, with increased survival rates.

The data was published in the current issue of the Vaccines journal, Vaxart ( VXRT ) said.

Vaxart ( VXRT ) shares rose 1.2% in Wednesday premarket activity.

Price: 0.8989, Change: +0.01, Percent Change: +1.20